To provide insight into the mechanisms that affect the anticancer efficacy of systemically administered ReHVs, we conducted kinetic clearance and biodistribution analyses of R-337 in the metastatic CT26-HER2 lung model in both tumor-free and tumor-positive mice. This evidence concerns the gene ERBB2 and neoplasm.